TMC435-TiDP16-C116 - Relative Bioavailability and Food Effect Study

Hepatitis C Clinical Trial

Official title:

A Phase I, Open-label, Randomized, Single-dose, 2-panel, Crossover Trial in Healthy Subjects to Assess the Relative Bioavailability of TMC435 HPMC Capsule Compared to the TMC435 Gelatin Capsule and to Assess the Effect of Different Meal Types on the Bioavailability of Both Formulations

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01308606
• Other study ID #: CR015940
• Secondary ID: TMC435-TiDP16-C1
• Status: Completed
• Phase: Phase 1
• First received: March 3, 2011
• Last updated: October 10, 2012
• Start date: March 2011
• Est. completion date: June 2011

Study information

• Verified date: October 2012
• Source: Tibotec Pharmaceuticals, Ireland
• Contact: n/a
• Is FDA regulated: No
• Health authority: Ireland: Irish Agriculture and Food Development Authority
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare absorption of TMC435 formulated as 2 different types of capsules. After that, the absorption of one chosen TMC435 capsule will be compared when taken under fasting conditions or together with a standard or a high-fat meal. This will be done in healthy volunteers.

Description:

This is an open-label, randomized, single-dose, crossover trial in healthy volunteers. Crossover means that participants may receive different interventions sequentially during the trial. Randomized means that you will be assigned to a treatment sequence by chance, like flipping a coin. Open-label means that you and your physician will know what treatment you will receive. The study will consist of 3 phases: a screening phase, a treatment phase and a follow-up phase. Total study duration for an individual participant will be up to 6 or 7 weeks. Once found eligible after the screening phase, participants will take part in one of the two parts of the treatment phase. In the first part, a group of 24 participants will receive two treatment sessions, A and B. The order in which the treatments are given will be determined by chance. Treatment A is a single dose of TMC345 as one formulation (1 capsule). Treatment B is a single dose of TMC435 as another formulation (1 other type of capsule). Both treatments will be taken without food. In between the 2 sessions, there will be at least 7 days. In the second part, another group of 24 participants will receive 3 treatment sessions, C, D, and E. The order in which these treatments are given will be determined by chance. All 3 treatments will consist of a single dose of TMC435 as one of the 2 formulations given in the first part. In Treatment C this will be given without food, in Treatment D with a standardized breakfast and in Treatment E with a high-fat breakfast. In between the sessions, there will be at least 7 days. For all treatment sessions, participants will enter the study center the day before dosing and will remain there until the evening of the day after. The 3 following mornings, participants will come back to the study center. Five to 7 days after dosing, participants will have a last follow-up visit at the study center (follow-up phase). During the study, safety will be monitored, and during the treatment phase, at specified timepoints, blood samples will be taken for pharmacokinetic evalutions (effect of the body on the drug). In every treatment session, a single oral 150 mg TMC435 capsule will be given. One formulation will be a gelatin capsule. The other formulation will be a hydroxypropylmethylcellulose (HPMC) capsule.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: June 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Non-smokers for at least 3 months prior to screening

• Have a body mass index of 18.0 to 30.0 kg per square meter

• Be healthy on the basis of physical examination, medical history, vital signs, and clinical laboratory tests performed at screening

Exclusion Criteria:

• Use of disallowed therapies, including over-the-counter products and dietary supplements

• Having previously participated in a multiple-dose trial or more than 3 single-dose trials with TMC435

• Received an investigational drug or used an investigational medical device within 90 days before the planned start of treatment

• History or evidence of current use of alcohol, barbiturate, amphetamine, recreational, or narcotic drug use

Study Design

Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hepatitis C

Intervention

Drug:
• TMC435 HPMC capsule
Single intake of one 150-mg capsule without food
• TMC435 HPMC or gelatin capsule
Single intake of one 150-mg capsule after high-fat breakfast
• TMC435 HPMC or gelatin capsule
Single intake of one 150-mg capsule without food
• TMC435 HPMC or gelatin capsule
Single intake of one 150-mg capsule after standardized breakfast
• TMC435 gelatin capsule
Single intake of one 150-mg capsule without food

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Tibotec Pharmaceuticals, Ireland

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Absorption of TMC435 following administration of the HPMC capsule and of the gelatin capsule		Over 72 hours for every treatment session	No
Primary	Absorption of TMC435 following administration of the HPMC or gelatin capsule in the fed (following different meal types) and fasted state		Over 72 hours for every treatment session	No
Secondary	Number of participants with adverse events and the severity of adverse events		During maximum 7 weeks	Yes
Secondary	Percentage of abnormal values for laboratory parameters		Up to maximum 7 weeks	Yes
Secondary	Observed values and changes from baseline of cardiovascular variables		Up to maximum 7 weeks	Yes
Secondary	Evaluation of pulse and blood pressure values, based on changes from baseline and the percentage of participants with values beyond clinically important limits		Up to maximum 7 weeks	Yes
Secondary	Physical examination findings and changes from baseline.		Up to maximum 7 weeks	Yes